ASCO 2023: aanbevolen abstracten voor gynaecologische vormen van kanker, waaronder baarmoederkanker, baarmoederhalskanker, eierstokkanker door vooraanstaande medisch specialisten

6 juni 2023: ASCO 2023:

In de week van 2 t/m 6 juni was er weer ASCO 2023. Hier een aantal aanbevolen abstracten gerelateerd aan eierstokkanker, baarmoederhalskanker , baarmoederkanker, vulvakanker en endometriumkanker door vooraanstaande artsen en oncologen wereldwijd.

Aanbevolen door Prof. Dr. Annette Hasenburg, directeur verloskunde en gynaecologie aan het Universitair Medisch Centrum van Mainz in Mainz, Duitsland, en lid van de adviesraad van PracticeUpdate Oncology.

Klik op de nummers van de abstracten om deze te lezen of te downloaden:

Saturday, June 3, 2023; 3:00 PM–6:00 PM CDT
Oral Abstract Session
Gynecologic Cancer

5500 KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer. B Monk, N Colombo, K Tewari, et al

5503 Dostarlimab for primary advanced or recurrent (A/R) endometrial cancer (EC): Outcomes by blinded independent central review (BICR) of the RUBY trial (ENGOT-EN6-NSGO/GOG-3031/RUBY). M Powell, S Hietanen, R Coleman, et al

Take-Home Message

Patients in the dostarlimab arm had a significantly and clinically meaningful improved progression-free survival after 24 months.
Therefore, dostarlimab + carboplatin/paclitaxel represents a new standard for patients with advanced or recurrent endometrial cancer.

5504 Patient-reported outcomes (PROs) in primary advanced or recurrent endometrial cancer (pA/rEC) for patients (pts) treated with dostarlimab plus carboplatin/paclitaxel (CP) as compared to CP in the ENGOT-EN6/GOG3031/RUBY trial. M Mirza, M Powell, C Lundgren, et al

5505 Randomized controlled phase III trial of weekly paclitaxel ± ofranergene obadenovec (VB-111) for platinum-resistant ovarian cancer (OVAL Study/GOG 3018). R Arend, B Monk, RS-Frommer, et al

LBA5506 Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial. P Harter, F Trillsch, A Okamoto, et al

Take-Home Message

This will be the first study to demonstrate the benefit of a combination therapy with a checkpoint inhibitor in primary ovarian cancer

5508 Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), safety and efficacy in a broad distribution of FolRα expression in patients with recurrent epithelial ovarian cancer (OC): Update of STRO-002-GM1 phase 1 dose expansion cohort. A Oaknin, L Fariñas-Madrid, C García-Duran, et al

Sunday, June 4, 2023; 7:30 AM–8:00 AM CDT
Oral Abstract Session
Gynecologic Cancer

LBA5507 Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression. K Moore, A Angelergues, G Konecny, et al

Take-Home Message

Mirvetuximab shows clinically relevant antitumor activity in patients with FRα-high platinum-resistant advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer.
This positions mirvetuximab to become a practice-changing, biomarker-driven standard of care.

Sunday, June 4, 2023; 9:45 AM–11:15 AM CDT
Specal Sessions
Clinical Science Symposium

105 Fecal microbiota transplantation combined with anti-PD-1 inhibitor for unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor. SR Park, G Kim, Y Kim, et al

Monday, June 5, 2023; 11:30 PM–2:30 PM CDT
Oral Abstract Session
Breast Cancer—Metastatic

1001 Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial. A Llombart-Cussac, C Harper-Wynne, A Perello, et al

Take-Home Message

In clinical practice, we often consider continuation of a CDK4/6 inhibitor beyond progression, especially in patients who have experienced long periods of disease control. The value of this approach has not been definitively answered, although the phase II MAINTAIN trial provided some support to it.
The PALMIRA trial evaluates whether palbociclib rechallenge combined with second–line endocrine therapy upon progression on a prior palbociclib–based therapy will improve progression–free survival over endocrine therapy alone in patients with HR+/HER2− metastatic breast cancer and will provide additional guidance regarding sequencing hormonal and targeted therapies in the metastatic setting.

1003 Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC). S Tolaney, A Bardia, F Marmé, et al

Take-Home Message

The availability of antibody–drug conjugates for the treatment of HR+/HER2− metastatic breast cancer has expanded treatment options for a considerable number of patients. As the goal of therapy is palliation, it is important to understand the efficacy and safety of these new agents, which will help to optimize sequencing therapies.
An overall survival benefit was previously reported for sacituzumab govitecan as compared with treatment of physician’s choice in the TROPICS-02 trial, and the current final overall survival analysis will be important to help further characterize the efficacy benefits seen with this potent antibody–drug conjugate.

Monday, June 5, 2023; 4:30 PM–6:00 PM CDT
Poster Discussion Session
Gynecologic Cancer

5517 A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The vulvar cancers. YK Chae, M Othus, S Patel, et al

ASCO 2023, gynaecologische vormen van kanker, eierstokkanker, baarmoederkanker, baarmoederhalskanker, vulvakanker, endometriumkanker, buikvlieskanker